We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





First-of-Its-Kind AI-Powered Solution Fully Automates Blood Morphology

By LabMedica International staff writers
Posted on 31 Jul 2025

While Complete Blood Counts (CBCs) have been automated for decades, laboratories still require a human in the loop during the Peripheral Blood Smear (PBS) review process. More...

PBS review remains labor-intensive, complex, and plagued by inefficiencies and variability, resulting in bottlenecks that affect turnaround times, scalability, and ultimately, patient care. These issues are amplified given the ongoing staffing crisis in clinical laboratories. Global workforce shortages, long training cycles, and increased demand for diagnostic tests have left labs struggling to maintain performance. Now, the unveiling of a novel analyzer at ADLM 2025 ushers in a new era of lab automation, analyzing 10x more cells than the current standard of care in blood cell morphology, addressing the global laboratory staffing crisis, and accelerating hematology workflows and efficiencies

Scopio Labs (Parsippany, NJ, USA) is unveiling its groundbreaking Complete Blood Morphology (CBM) analyzer, bringing unprecedented scale, efficiency, and standardization to hematology through autonomous morphology analysis and reporting, one of the last remaining manual processes in diagnostics. CBM is built on top of Scopio's proprietary Full-Field technology, leveraging advanced computational imaging and AI-powered analysis to transform the current PBS review workflow into an autonomous, standardized, and clinically relevant process, analyzing 10x more cells than the current standard of care in blood cell morphology. Hematology labs currently utilizing Scopio's Full-Field PBS platform are already alleviating some of the pain points, while laying the essential groundwork for rapid CBM adoption, effectively future-proofing their operations.

"Our vision is to be the first to close the automation gap in hematology by developing a fully integrated and automated hematology process from CBC to final result," said Itai Hayut, CEO and Co-founder at Scopio Labs. "This isn't just a small step forward, it could potentially reshape the whole market by changing the workflow, the economics, and creating an entirely new market category. With CBM, the market can evolve from current digital lab solutions that help people make decisions, to a system that's designed to deliver fully automated results with the goal of eliminating the need for routine human morphology review altogether. Beyond that, we also believe that this technology will pave the way to developing accurate and consistent morphology-based biomarkers and diagnostic panels, which can be used for early detection and monitoring of disease directly from blood."

Related Links:
Scopio Labs


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hemodynamic System Monitor
OptoMonitor
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.